Page 2 - Vector Manufacturing News Today

DUBLIN--(BUSINESS WIRE)--The "Gene Therapy Market by Type of Therapy, Type of Gene Delivery Method Used, Type of Vector Used, Target Therapeutic Areas, Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.Ge...

Viral and Non-Viral Vector Manufacturing Market Size, Growth, Demand, Trends, Analysis and Forecast Report by 2027

/PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that the Company...

/PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts...

/PRNewswire/ -- The "Viral Vector Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.coms offering. Global...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Dublin, Jan. 07, 2022 (GLOBE NEWSWIRE) -- The "Technology Developments in Viral Vector Manufacturing for Cell and Gene Therapies" report has been added...

Share: WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced results from preclinical studies presented in poster and oral sessions at the American Society of Gene and Cell Therapy (ASGCT) 24 Challenges in achieving adequate expression in the central nervous system (CNS) with conventional...